Brevan Howard Capital Management LP Arcutis Biotherapeutics, Inc. Transaction History
Brevan Howard Capital Management LP
- $17 Billion
- Q3 2025
A detailed history of Brevan Howard Capital Management LP transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 25,201 shares of ARQT stock, worth $630,025. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,201
Previous 43,934
42.64%
Holding current value
$630,025
Previous $615,000
22.76%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ARQT
# of Institutions
252Shares Held
127MCall Options Held
404KPut Options Held
133K-
Jennison Associates LLC12.3MShares$306 Million0.14% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$269 Million3.33% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.5MShares$262 Million5.93% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$247 Million7.87% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$216 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $1.5B
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...